Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemarituzumab
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bemarituzumab is a first-in-class, humanized, afucosylated IgG1 kappa monoclonal antibody that selectively targets the extracellular domain of fibroblast growth factor receptor 2b (FGFR2b), a splice variant of FGFR2. By binding to FGFR2b, it blocks fibroblast growth factors from activating the receptor, thereby inhibiting downstream pro-tumor signaling pathways and potentially slowing cancer progression. Bemarituzumab also enhances antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing FGFR2b. It is being developed primarily for the treatment of previously untreated locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma with FGFR2b overexpression, in combination with chemotherapy. The drug is also under investigation for other solid tumors that overexpress FGFR2b[3][5][8].
- Other names
- bemarituzumab
02
Targets
FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on bemarituzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemarituzumab.